Medical News

RSS

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

Masimo, the inventor of Rainbow Pulse CO-Oximetry™, Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced the international limited market release of Masimo Pronto-7 -- a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing in virtually any environment.

23 Jun 2010

University of Colorado honors Taligen as Bioscience Company of the Year

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has been selected as the Bioscience Company of the Year by the University of Colorado with its 7th Annual Technology Transfer Awards in recognition of its leadership position in developing a pipeline of novel protein therapeutics that modulate the complement system to treat a wide range of inflammatory diseases.

23 Jun 2010

InfoLogix engages KPMG as independent registered public accounting firm

InfoLogix, Inc., a leading provider of enterprise mobility solutions for the healthcare and commercial industries, announced today that the Audit Committee of the Board of Directors has engaged KPMG, LLP to serve as the Company's independent registered public accounting firm for the year ending December 31, 2010.

23 Jun 2010

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

Window World selected to receive New Corporate Partner of the Year award

Window World, the nation's largest replacement window company, has been selected by St. Jude Children's Research Hospital to receive the hospital's celebrated "New Corporate Partner of the Year" award, given out annually to a new partner who demonstrates excellence and dedication in fundraising. A St. Jude corporate partner since 2008, Window World has raised more than $1 million for the hospital, which is one of the world's premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases.

23 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

San Francisco dentist recognized with Presidential Award at SCDA's annual national meeting

Dr. David Blende of San Francisco was recognized for his many years of service to the Special Care Dentistry Association when the organization presented Dr. Blende with their Presidential Award. The Awards Ceremony took place Sunday, March 28, 2010, at the SCDA's annual national meeting at the Swissotel in Chicago.

23 Jun 2010

California Providence hospitals select Allscripts for new homecare automation systems

Providence Saint Joseph Medical Center of Burbank, Calif., and Providence Little Company of Mary Medical Center of Torrance, Calif., announced they have selected Allscripts for their new homecare automation systems.

23 Jun 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

$Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors$

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.

23 Jun 2010

Grant introduces new range of digital, analogue ultrasonic benchtop baths

Grant Instruments, a world-renowned supplier of scientific, life sciences and data acquisition products, has unveiled an advanced range of high quality, robust, fully-featured digital and analogue ultrasonic benchtop baths. The baths are designed to meet the growing need for reliable ultrasonic cleaning in laboratories and across pharmaceutical, medical, healthcare and industrial applications.

23 Jun 2010

BASF signs agreement to acquire Cognis for equity purchase price of euro 700 million

BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.

23 Jun 2010

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.

23 Jun 2010

New research project to review accuracy of medical diagnoses

A new research project at the University of Leicester will review the accuracy of medical diagnoses. Evaluating diagnostic strategy is crucial to clinical practice as it helps maximise the efficacy of the treatments which are offered to patients. Many lives are affected every day by the diagnoses made by hospitals and medical doctors, and it is vital that diagnoses are accurate.

23 Jun 2010

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

The human body contains more bacteria than it does cells. These bacterial communities can have a positive effect on our health, by training our immune systems and helping to metabolize the foods we eat. But they can also set us up to develop digestive disorders, skin diseases, and obesity.

23 Jun 2010

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals, Inc. announced today it will present new analyses from the FREEDOM-301 Phase 3 clinical trial in a late breaker session at the 52nd Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, California on Friday, June 25 from 3:30 to 4:00 pm PT. The presentation will show that the Company's investigational LEVADEX™ orally inhaled migraine therapy was effective irrespective of when it was administered during a migraine cycle.

23 Jun 2010

Company took measures to protect employees from H1N1 flu: National poll

In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.

23 Jun 2010

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

Migraine sufferers who experienced abuse and neglect as children have a greater risk of cardiovascular (CV) disease including stroke and myocardial infarction (MI) among others, say scientists presenting data at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week.

23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Medical News

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

University of Colorado honors Taligen as Bioscience Company of the Year

InfoLogix engages KPMG as independent registered public accounting firm

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

Window World selected to receive New Corporate Partner of the Year award

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

San Francisco dentist recognized with Presidential Award at SCDA's annual national meeting

California Providence hospitals select Allscripts for new homecare automation systems

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

Phase 1 clinical trial of XMT-1107 initiated in patients with refractory advanced solid tumors

Grant introduces new range of digital, analogue ultrasonic benchtop baths

BASF signs agreement to acquire Cognis for equity purchase price of euro 700 million

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

New research project to review accuracy of medical diagnoses

Shift in balance between good and bad bacteria in gut could be a harbinger of colon cancer: Study

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

Company took measures to protect employees from H1N1 flu: National poll

Early adverse experiences influence migraine sufferers' cardiovascular health in adulthood

UK cancer survival rates increase at 3% each year

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News